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Introduction
Familial Mediterranean fever (FMF) is an autosomal reces-
sive disease, characterized by recurrent, self-limited attacks
of fever with serositis involving the peritoneum, pleura and
joints; and colchicine is its universal treatment.
Objectives
To explore whether the demographic and clinical fea-
tures of FMF patients with different colchicine response
vary or not.
Methods
Files of patients who had been seen in our department
(during routine follow-up visits) between January 2009
and January 2013 were retrospectively evaluated.
Results
The study group comprised 221 FMF patients (116F,
105M) with a mean age of 12.7±5.3 years. Mean dura-
tion of colchicine use was 58.9±45.3 months. Patients
were divided into two groups according to their colchi-
cine response; Group I (n=131) included patients with
no attacks after colchicine and Group II (n=90) patients
with partial or no response to colchicine. Mean age, sex,
age at disease onset, age at colchicine onset, family his-
tory of FMF, attack frequency, attack duration, clinical
features during attacks, duration of colchicine use and
M694V carriage were similar between the groups. Final
colchicine doses, disease severity scores, acute phase
reactant levels (during attack free period) were signifi-
cantly higher in Group II when compared with those of
Group I (p<0.5).
Conclusion
Colchicine response seems to be related with disease
severity scores and acute phase reactant levels (during
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